Antiviral Activity of Indonesian Medicinal Plants against Hepatitis B Virus

Tutik Sri Wahyuni1,2,*, Adita Ayu Permanasari2, Aty Widyawaruyanti1,2, Hak Hotta3,4, Chie Aoki-Utsubo4, Achmad Fuad Hafid1,2

ABSTRACT

Background: Hepatitis B virus (HBV) infects more than 300 million people globally and is a common cause of liver cancer. Current therapy using reverse transcriptase inhibitors require long-term treatment and the potential risk of development of drug-resistant viruses remains an important issue to be considered. Hence, the development of new drugs is critical. Traditional medicinal plants used for the treatment of infectious diseases may provide a viable option for the discovery of anti-HBV drug candidates. Objective: This study examined antiviral activity of 31 kinds of Indonesian plants. Materials and Methods: Crude extracts of various parts of plants, leaves and stem, were obtained using dichloromethane and ethanol solvent. The effect on viral entry was examined by determining levels of HBsAg expression in the supernatants of HBV-infected HepG2-NTCP cells by ELISA. The effect on HBV replication was determined by measuring HBV DNA amounts in Hep38.7-Tet cells by quantitative real-time PCR. Results: The extracts of Phyllanthus niruri leaves and Curcuma xanthorrhiza showed reduction of strong HBsAg production from HepG2-NTCP cells with IC50 values of 170.48 and 270.51 μg/mL, respectively. Treatment of HepAD38.7-Tet cells with P. niruri and C. xanthorrhiza at the highest concentration while avoiding cytotoxicity reduced extracellular HBV DNA levels by 70% and 30% of the untreated control respectively. Conclusion: P. niruri inhibited both the entry and HBV replication, thus P. niruri is a promising candidate for anti-HBV drug development. Key words: Hepatitis B Virus, Phyllanthus niruri, Curcuma xanthorrhiza, Medicinal plants.

INTRODUCTION

Hepatitis B Virus (HBV), a member of the Hepadnaviridae family, is an enveloped virus with partially double-stranded circular DNA genome that attacks the liver and causes both acute and chronic HBV infections. Chronic HBV infections result in liver cirrhosis and hepatocellular carcinoma (HCC).1 It has been estimated that approximately 257 million people are living with chronic hepatitis B infection resulting in circa 887 000 deaths annually.2 Transmission of HBV infection occurs when an uninfected person comes into contact with infected blood and/or body fluids (e.g., semen, vaginal secretions, etc) through sexual activity, sharing of personal items, contaminated medical equipment and mother to child transmission during birth.3 To support HBV prevention, a HBV vaccine has been developed, which is safe, and effective as a routine prophylactic by inducing the appropriate immune response in the host.4 In contrast, once an infection has occurred, the current antiviral treatments for the suppression of HBV replication are used. Interferon (IFNs) and nucleos(t)ide analogues (NAs) have been used and demonstrated to prevent cirrhosis, liver failure and HCC which is caused by HBV infection.5 However, the long-term treatment with (NAs) and interferons is associated with an increased risk of side effects and potential drug resistance.6 Therefore, it is necessary to develop a new therapy or alternative medicine against HBV infection.

Medicinal plants are rich in various secondary metabolites that have been used to cure several kinds of human disease. It is interesting that about 80% of the active ingredient which have been isolated from plants indicate a positive correlation between modern and traditional therapeutic uses.8 Some of these plants, such as Curcuma longa Linn,9 Ganoderma lucidum,10 Acanthus ilicifolius L,11 and Oenanthe javanica12 have been reported to exhibit anti-HBV activity. Several compounds (periglaucines A–D, norruccinse, (–)-8-oxotetrahydropalmatine) isolated from Pericampylus glaucus, showed anti-HBV activity on HepG2.2.15 cell line in vitro. Compounds of 8-oxotetrahydropalmatine could inhibit HBsAg secretion with an 50% inhibition concentration (IC50) value of 0.14 mM (SI = 22.4). It has also been reported that pipeline and guinesine, isolated compounds of Piper longum, exhibit inhibitory activity suppressing the secretion of HBsAg and HBeAg with IC50 values of 0.15 and 0.05 mM for HBsAg, and 0.14 and 0.05 mM for HBeAg, respectively.13 Our previous study was reported Cananga odorata possessed a strong anti-HBV activity both in HepG2-NTCP and Hep38.7-Tet cells which indicated the action of extract in the entry and post entry steps (replication) of HBV life cycle.14 In this study, we screened 31 samples of Indonesian medicinal plants for anti-HBV activity by two in-vitro assays to assess the effect on the viral entry and replication.

MATERIALS AND METHODS

Plant material

A total of 37 plants were collected from the National Botanical Garden of Balikpapan Kalimantan Timur and Malang, East Java, Indonesia (Table 1). Plants were identified by an experienced Botanist at the National Botanical Garden, Malang, East Java, Indonesia.

Cell lines and virus

HepG2-NTCP cells were used to assess the antiviral effect on the viral entry. These cells are known to express sodium taurocholate co-transporting polypeptide (NTCP) that has been identified as a functional receptor for HBV. Post-entry inhibition was analyzed using Hep38.7-Tet cells that expressed viral HBV pgRNA under tetracycline provision. The viruses that were produced from Hep38.7-Tet were used to infect HepG2-NTCP cells. To enhance the infection process, PEG was added during virus infection. The HepG2-NTCP cells were cultivated using Dulbecco’s Modified Eagle Medium/Nutrient Mixture F12 with GlutaMAX (Thermo Fisher Scientific, Carlsbad, CA), supplemented with 10% FBS, 10 mM HEPES, 5 µg/ml insulin (Fujiifilm Wako), 100 IU/ml penicillin/streptomycin, and 1 mg/ml G418 (Nacalai Tesque), while the Hep38.7-Tet was grown in basal culture medium with a composition similar to that used for the HepG2-NTCP cells, but with the addition of 400 µg/ml G418 and 400 ng/ml tetracycline (Fujiifilm Wako). All cells were maintained at 37°C and 5% CO2 atmosphere in a humidified incubator.

Plant extraction

Several different solvents (ethanol 80%, hexane, and dichloromethane) were used to extract from the leaf and stem samples. The leaves were extracted using n-hexane and ethanol 80%. Meanwhile, the residue from the n-hexane extract underwent a further extraction process using dichloromethane (DCM). In this study we used dichloromethane extracts from samples collected in Balikpapan, Indonesia while ethanol 80% extract was used for the East Java collection. All extracts were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mg/ml and then stored at -30°C.

HBV entry inhibition screening

The HepG2-NTCP were seeded in a 24 well plate for 24 hours before the assay was performed. Cells were inoculated with HBV in the presence of a single concentration of plant extract (100 µg/ml) for the screening assay. The activity of plant extract was examined at different concentrations (400; 200; 100; and 50 µg/ml) to obtain the IC50 value. The mixture of HBV and extract was inoculated onto HepG2-NTCP for 16 hours. Cells were subsequently washed to remove the extract and excess virus. The cells growth medium was replaced every 2 days until day 8. Supernatants were then collected to perform ELISA HBsAg screening (Abnova, HBsAg ELISA kit). Briefly, samples and control treatments at a concentration of 50 µl were added into well plates of the kit, then 50 µl of anti-HBsAg-peroxidase solution was added. The plate was incubated at 37°C for 30 minute and washed with PBS 10 times. To mix the tetramethylbenzidine (TMB) substrate, solution A and B were added by equal volume of 100 µl/well and then incubated for 30 minutes. To stop the reaction, 100µl of 2N H2SO4 were added in each well and absorbance was determined within 30 minutes at 450/650 nm.

HBV post-entry inhibition assay

Hep38.7-Tet cells were used to assess the effect of extract on the post-entry stage of HBV infection. Cells were seeded in a 24 well plate for 24 hours before the assay was performed. Sample was added to the cells at four different concentrations (200, 100, 50, 25 µg/ml) without tetracycline provision, while the positive control was amended with tetracycline to suppress HBV production. In conditions free from tetracycline, Hep38.7-Tet will produce HBV pg RNA and released it into the supernatant of the culture. The plate was incubated for 16 hours then medium free extract was used to wash the extract residue after 16hr. The medium extract was added every 3 days until day 7. Supernatant was then collected for DNA purification. Real Time (RT)-qPCR was performed to quantify the amount of extracellular HBV DNA in each sample. Briefly, the HBV DNA was purification by centrifugation column filtering (Promega Midi DNA kit purification). The DNA was amplified for real-time quantitative PCR using SYBR Premix Ex Taq (Takara Bio, Shiga, Japan) with specific primers for the HBV genome: Ayw-F (5′-TCTGGTGTTGAGCTTCTC-3′) and Ayw-R (5′-AAATGGAGGGCCATGCGGCA-3′). The cytotoxicity of samples was assessed on selected plants by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. Briefly, cells in 96 well plates were treated with various concentrations of crude extracts for 48 hours. The medium was replaced with MTT containing medium and incubated for 4 hours. Insoluble precipitates were dissolved with DMSO and absorbance was measured using a microplate reader. The cell viability percentages were determined using the absorbance at 570 nm.

Table 1: Medicinal plants tested for anti-HBV activity in HepG2-NTCP cell culture.

<table>
<thead>
<tr>
<th>No</th>
<th>Species Name</th>
<th>Code</th>
<th>Family</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Melicope glabra (Syn M. pinnata)</td>
<td>BP01</td>
<td>Rutaceae</td>
</tr>
<tr>
<td>2</td>
<td>Laurus TAXUS (Roxb.) Wight</td>
<td>BP02</td>
<td>Rutaceae</td>
</tr>
<tr>
<td>3</td>
<td>Artocarps sericarpus</td>
<td>BP03</td>
<td>Moraceae</td>
</tr>
<tr>
<td>4</td>
<td>Artocarps dadah</td>
<td>BP04</td>
<td>Moraceae</td>
</tr>
<tr>
<td>5</td>
<td>Scorodorcarpus borneensis</td>
<td>BP06</td>
<td>Olacaceae</td>
</tr>
<tr>
<td>6</td>
<td>Equisetoxylon zaveri</td>
<td>BP07</td>
<td>Lauraceae</td>
</tr>
<tr>
<td>7</td>
<td>Fagaceae racemosa</td>
<td>BP08</td>
<td>Loganiaceae</td>
</tr>
<tr>
<td>8</td>
<td>Pterandra galeata</td>
<td>BP09</td>
<td>Melastomataceae</td>
</tr>
<tr>
<td>9</td>
<td>Fordia splendidaissima</td>
<td>BP11</td>
<td>Fabaceae</td>
</tr>
<tr>
<td>10</td>
<td>Aglaia lawii</td>
<td>BP13</td>
<td>Meliaceae</td>
</tr>
<tr>
<td>11</td>
<td>Gonocaryum titorale</td>
<td>BP15</td>
<td>Icacinaceae</td>
</tr>
<tr>
<td>12</td>
<td>Orophesia hexandra</td>
<td>BP16</td>
<td>Lauraceae</td>
</tr>
<tr>
<td>13</td>
<td>Gymnacanthera fargushariana</td>
<td>BP18</td>
<td>Lauraceae</td>
</tr>
<tr>
<td>14</td>
<td>Alseodaphne elmeri</td>
<td>BP19</td>
<td>Lauraceae</td>
</tr>
<tr>
<td>15</td>
<td>Neolitsea cassisfolia</td>
<td>BP20</td>
<td>Lauraceae</td>
</tr>
<tr>
<td>16</td>
<td>Vernonia arboare</td>
<td>BP21</td>
<td>Asteraceae</td>
</tr>
<tr>
<td>17</td>
<td>Ficus geocaris</td>
<td>BP22</td>
<td>Moraceae</td>
</tr>
</tbody>
</table>

Plant extraction

Several different solvents (ethanol 80%, hexane, and dichloromethane) were used to extract from the leaf and stem samples. The leaves were extracted using n-hexane and ethanol 80%. Meanwhile, the residue from the n-hexane extract underwent a further extraction process using dichloromethane (DCM). In this study we used dichloromethane extracts from samples collected in Balikpapan, Indonesia while ethanol 80% extract was used for the East Java collection. All extracts were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mg/ml and then stored at -30°C.

Cytoxicity assay

The cytotoxicity of samples was assessed on selected plants by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. Briefly, cells in 96 well plates were treated with various concentrations of crude extracts for 48 hours. The medium was replaced with MTT containing medium and incubated for 4 hours. Insoluble precipitates were dissolved with DMSO and absorbance was measured using a microplate reader. The cell viability percentages were determined using the absorbance at 570 nm.
were compared to the control and facilitation calculation of the 50% cytotoxic concentration (CC₅₀) values. In this study, the cytotoxicity assay was performed both in HepG2-NTCP and Hep38.7-tet.

RESULTS

Anti-HBV screening of entry stage inhibition and cytotoxicity assay of selected active extracts

Among 31 plant extracts evaluated for anti-HBV activity on the viral entry step, two extracts exhibited strong reduction of HBs production in HepG2-NTCP cells (Figure 1). The extract of P. niruri at a concentration of 100 μg/mL showed 48.2% inhibition, while the extract of C. xanthorrhiza exhibited 29.0% inhibition. P. niruri had the strongest antiviral activity with IC₅₀ values of 170.48 µg/mL and CC₅₀ values of >400 µg/mL. In contrast, C. xanthorrhiza extracts showed an IC₅₀ value of 270.51 µg/mL and CC₅₀ of >206.69 µg/mL (Figure 2).

Antiviral HBV screening of post-entry stage inhibition and cytotoxicity assay

To evaluate the active extract in the post-entry step, further analysis was conducted via Hep38.7-Tet cells culture. As can be seen in Figure 3, the post-entry inhibition assay reflected the ability of P. niruri to dramatically reduce extracellular HBV DNA levels. Various concentrations were tested and this showed a dose dependent antiviral effect in the post-entry step without any toxicity developing at a dose of 100 µg/mL. This result indicated that P. niruri may inhibit HBV replication, assembly, and virion release. The cytotoxicity of P. niruri extract in Hep38.7-tet showed did not suppress the viability of cells with a CC₅₀ value exceeding 274.51 µg/mL. In contrast, the extract of C. xanthorrhiza inhibited post-entry stage infection with a 30% reduction of HBV DNA levels at a concentration of 50 µg/mL. Furthermore, C. xanthorrhiza exhibits greater toxicity than P. niruri extract (Figure 3).

DISCUSSION

Medicinal plants are promising candidates for drug discovery due to their interesting chemical metabolites. It has been previously reported that various compounds isolated from these plants display promising bioactivity. Medicinal plants from various countries have been tested for anti-HBV to find potential candidates for anti-HBV drug development. The goal of HBV therapy is to prevent the progression of chronic hepatitis B to cirrhosis, end-stage liver disease, hepatocellular carcinoma and death. It has also been postulated that some medicinal plants used in Traditional Chinese Medicine exhibit anti-HBV activity. Several plants native to the Arabian Peninsula: Guiera senegalensis, Pulicaria crispa, Coccinea grandis, Fumaria parviflora, Capparis decidua, Corallocarpus epigeus, Indigofera cuerulea, Abutilon figuranum and Acacia aertifolia have also been found to possess anti-HBV activity by inhibiting hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in the cell culture supernatant. Our previous study also reported that Cananga odorata exhibited strong inhibition of the hepatitis B virus in Hep38.7-Tet and HepG2-NTCP cells. In this study we evaluated a number of medicinal plants for anti-HBV which have been reported to show anti-viral activity. The plants were selected based on empirical used and preclinical empirical studies. We examined the abilities of 31 Indonesian medicinal plants to inhibit the entry step of HBV into HepG2-NTCP and the levels of extracellular...
HBV DNA on HepAD38.2 cells. In the HBV life cycle, after infecting hepatocyte cells, the virus will undergo several steps, including, attachment, endocytosis, and release of capsid. Following this, the relaxed circular HBV DNA genome is converted into covalently closed circular DNA (cccDNA). The replication process includes transcription, translation, encapsidation, reverse transcription, DNA synthesis, budding the virion and release. NTCP is a receptor for HBV entry, which is overexpressed in the HepG2-NTCP cell line used to evaluate anti-HBV activity in the entry step. The other cell line, Hep38.7-Tet, was a tetracycline inducible hepatitis B virus expressing cell line. Replication of the virus can be induced in this cell line and, therefore, it is suitable for detecting inhibition in the post-entry step as well as replication of virus. Our research demonstrated that the extracts of *P. niruri* and *C. xanthorrhiza* exhibited anti-HBV activities of a greater magnitude than the other plant extracts tested. *P. niruri* inhibited viral entry with an IC50 value of 170.5 µg/ml and CC50 value of >400 µg/mL and inhibited post-entry steps (extracellular HBV DNA was reduced reduced) without exhibiting cytotoxicity. In contrast, *C. xanthorrhiza* showed a toxic effect in HepG2-NTCP and Hep38.7-Tet cells at a concentration of 200 µg/ml and did not inhibit HBV replication in Hep38.7-Tet cells. *P. niruri* is a plant that is found in many areas across tropical and subtropical regions. The genus of Phyllanthus (Euphorbiaceae) has been used for various traditional medicines in many countries, including in Indonesia. It has been reported to exhibit varied and interesting biological activities, including stomachic, diuretic, febrifuge, deobstruent, and antiseptic activity and has used in effective remedies for hepatopathy. The various species of the Phyllanthus family, such as the *P. amarus*, *P. niruri*, *P. urinaria*, and *P. orbicularis*, have been reported to inhibit a broad spectrum of viruses. Previous work showed that these plants may...
inhibit human immunodeficiency virus (HIV) and herpes simplex virus (HSV). It has been reported that extracts from Phyllanthus species have a positive effect on the antiviral activity and serology response of HBsAg in HBV carriers. It was also demonstrated that the extract of Phyllanthus amarus suppresses hepatitis B virus by interrupting the interaction between HBV enhancer I and cellular transcription factors, resulting in an inhibition of polymerase activity and mRNA transcription. Our findings demonstrate a different mechanism of anti-HBV activity for P. niruri.

P. niruri contains numerous compounds, including alkaloids, flavonoids, lignans, phenols, and terpenes, which display equally varied biological activities including antiviral activity. Phyllanthin and hypophyllanthin are the lignin compounds that were found to be major components of P. niruri. Phyllanthin was predicted to interact with the entry receptors of the hepatitis virus and exhibit hepatoprotective activities. Niranthin and hinokinin isolated from P. amarus strongly inhibit hepatitis B activity while Corilagin was reported to block HCV NS3 protease and NS5B RNA-dependent-RNA-polymerase.

In contrast to P. niruri, C. xanthorrhiza was widely used in many traditional medicines as an anticancer, anti-microbial, anti-inflammatory, anti-oxidant, anti-hyperglycemic, anti-hypertensive, anti-platelet and nephroprotective. The ethanol extracts of C. xanthorrhiza have been demonstrated to reduce fatty liver symptom and inhibit alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and protein content. The isolated compound from the fresh rhizome, xanthorrhizol, expresses antimicrobial activity against pathogenic bacteria and fungi. Extracts of C. xanthorrhiza have previously been demonstrated to exhibit anti-hepatitis C virus activity. Our study showed C. xanthorrhiza has marginal inhibitory effect on HBV entry step.

CONCLUSION

Among 31 plant extracts, P. niruri exhibited the greatest anti-HBV activity on both the viral entry step and viral replication. This plant is promising candidate for anti-HBV drug development.

CONFLICTS OF INTEREST

None.

ACKNOWLEDGEMENTS

We thank Dr. Koichi Watashi and Dr. Takaji Waka (National Institute of Infectious Diseases, Tokyo, Japan) for providing Hep38.7-Tet and HepG2-NTCP cells. This work was supported by Research Institute and Inovation, Airlangga University through Riset Mandat Grant, FY2018 LIPI-JSPS bilateral joint research project, and Inamori Foundation.

REFERENCES


**ABOUT AUTHORS**

**Tutik Sri Wahyuni**, PhD. is a lecturer at Department of Pharmacognosy and phytochemistry Faculty of Pharmacy and a researcher in at Natural Product Medicine Research and Development (NPMRD), Institute of Tropical Disease, Universitas Airlangga. She took her PhD at Kobe University, Graduate School of Medicine2 and studied on anti-hepatitis C virus activities of medicinal plants and its metabolites. Now, she focusses on drug development for hepatitis virus infection of medicinal plants.

**Adita Ayu Permanasari**, MSc, is a researcher in Institute of Tropical Disease, Universitas Airlangga, Indonesia. She graduated in Master of Biology from Faculty of Science and Technology, Universitas Airlangga. She is currently work on antihepatitis virus cell culture and its mechanism of action. Some studies of hepatitis viruses have been published in some international scientific journals.
Dr. Aty Widyawaruyanti is a lecturer at Faculty of Pharmacy, Universitas Airlangga and researcher at Natural Product Medicine Research and Development (NPMRD), Institute of Tropical Disease, Universitas Airlangga. She obtained her bachelor degree in Pharmacy at Faculty of Pharmacy, Padjajaran University. She was further pursued her Master and Doctoral degree at Faculty of Pharmacy, Universitas Airlangga. Her research is focuses on drug discovery from bioactive natural products especially drug discovery for antimalarial drugs and other infectious diseases.

Professor Hak Hotta. Professor at Faculty of Nutrition and Clinical Dietetics, Konan Women's University
Professor Emeritus at Kobe University (Medicine)
M.D. (Osaka University School of Medicine)
Ph.D. (Kobe University Graduate School of Medicine)
Professional Career:
Visiting Scientist at Wistar Institute in 1986–1987
Professor and Chair (Microbiology) at Kobe University School of Medicine in 1994–2015
Endowed Professor at Kobe University Graduate School of Health Sciences in 2015–2018
Professor at Konan Women's University since 2018
Concurrent International Professional Career
Adjunct Professor at University of Indonesia
Honorary Professor at Airlangga University

Chie Aoki-Utsubo, Ph.D
Graduated from School of Pharmacy, Nihon University in 2002 and completed my Ph.D. from the University of Shizuoka, Japan in 2007. The doctoral thesis was focused on identification and characterization of the carbohydrate molecule which is associated with entry of Dengue virus type 2 to the mammalian cells. Then, I worked on development of new system for screening of anti-hepatitis C virus (HCV) drugs as a post-doctoral researcher (2007-2010) and screening of anti-HCV substances from Indonesian medicinal plants as a project assistant professor (2010-2014). Since 2015, I have worked as an associate professor at Kobe University Graduate School of Health Sciences, Japan and studied on antiviral mechanism of natural compounds exhibiting antiviral activities against hepatitis B, C, and dengue viruses.

Professor Achmad Fuad Hafid is currently vice-director of Institute of Tropical Disease, Universitas Airlangga. He is a lecturer at Faculty of Pharmacy, Universitas Airlangga and a researcher as well. His acquired a Professor with expertise in the fields of phytochemistry and bioactive natural product discovery for therapeutics applications.